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Various studies have reported that Huaier possesses anti-tumor effects. However, the mechanisms
are not completely elucidated. Here, we found 66 differentially expressed miRNAs in Huaier-treated
pulmonary adenocarcinoma A549 cells, with upregulation of miR-26b-5p. Transfection of A549 cells
with miR-26b-5p mimic inhibited proliferation and induced apoptosis, while transfection of Huaier-
treated A549 cells with a miR-26b-5p inhibitor reversed the effects of Huaier. EZH2 was veriﬁed as
the target of miR-26b-5p. Thus, our ﬁndings indicate that Huaier might suppress proliferation and
induce apoptosis in lung cancer cells via a miR-26b-5p-EZH2-mediated approach, which provides a
new perspective for understanding the anti-tumor effects of Huaier.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction [7,8], inhibition of angiogenesis [9]. Nevertheless, the underlyingLung cancer is the second most commonly diagnosed cancer
and the leading cause of cancer-related death in both men and
women in the United States [1]. There is now growing importance
to develop safer, natural, non-toxic compounds as chemotherapeu-
tic/chemopreventive agents. In this regard, traditional Chinese
medicines (TCMs) have recently gained attention as possible anti-
cancer agents with few side effects [2,3].
Trametes robiniophila murris (Huaier) is a fungus found in China
and has been applied in TCM for approximately 1600 years [4].
However, the necessary clinical studies have only been conducted
in recent years. Proteoglycans, which contain 41.53% polysaccha-
rides, 12.93% amino acids, and 8.72% water, have been identiﬁed
as the major effective ingredients of Huaier extracts [5,6]. Recently,
accumulating evidence has indicated that Huaier has antitumor
activities, such as stimulation of apoptosis in breast cancer cellsmechanisms of Huaier activities in lung cancer remain unclear.
MicroRNAs (miRNAs) are small, non-coding, endogenous RNAs
that regulate gene expression at the post-transcriptional level.
Many studies have shown that aberrantly expressed miRNAs may
act as oncogenes or tumor suppressors involved in the tumorigen-
esis and aggression of human cancers [10,11]. Since miRNAs play
crucial roles in human cancer, we hypothesized that miRNAs
may be involved in mediating the antitumor effects of Huaier.
In the present study, to investigate involvement of miRNA in the
effects of Huaier, we examined the differences in the miRNA
expression proﬁles of Huaier-treated and untreated A549 cells by
miRNA microarray analysis, and then explored the potential role
of speciﬁc miRNA in anti-tumor effects of Huaier. Our data pro-
vided important insights into the mechanisms of anti-tumor effect
of Huaier.
2. Materials and methods
2.1. Cells and cell culture
Human embryonic kidney (HEK) 293T and non-small cell lung
cancer (NSCLC) cell lines, including A549, H1299, H1975, Hcc827,
Fig. 1. Huaier inhibited proliferation and induced apoptosis in A549 cells (A) A549
cells were treated with the indicated concentrations of Huaier for the indicated
times, and cell proliferation was evaluated by CFSE assay. proliferation index (P.I.)
values represent the mean ± SD.(B and C) Huaier induced A549 cell apoptosis in a
concentration- and time-dependent manner. Cells apoptosis was analyzed by ﬂow
cytometry. The percentages of apoptotic cells compared with control cells are
shown (n = 3, mean ± SD). ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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(ATCC). Lung carcinoma 95-D cells were obtained from the Cell
Bank of the Chinese Academy of Science. A549, 95-D, H1299,
Hcc827, and H1975 cells were cultured in RPMI-1640 (Hyclone,
UT, USA). HEK293T and H460 were maintained in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM, Gibco, CA, USA). All media were sup-
plemented with 10% fetal bovine serum (Hyclone), 100 U/mL
penicillin, and 100 lg/mL streptomycin (Thermo, CA, USA). All cells
were incubated in a humidiﬁed atmosphere of 5% CO2 at 37 C in
an incubator.
2.2. Preparation of Huaier
Electuary ointment of Huaier (Gaitianli, Jiangsu, China) was dis-
solved in phosphate-buffered saline (PBS) to obtain a 100 mg/mL
stock solution. The solution was then sterilized with a 0.22-lm ﬁl-
ter and stored at 20 C before use.
2.3. Cell proliferation assay
Cell proliferation was analyzed using the carboxyﬂuorescein
diacetate succinimidyl ester (CFSE) labeling method (Invitrogen,
CA, USA). The stock solution of CFSE was 5 mM. A549 cells were
suspended in PBS with 5 lM CFSE (5  106 cells/mL) for 15 min
at 37 C to stabilize CFSE labeling. Labeled A549 cells were then
seeded into 12-well plates at a density of 1  105 cells/well. After
24 h, A549 cells were treated with Huaier or transfected with miR-
NA mimic, inhibitor, or EZH2 shRNA. CFSE ﬂuorescence was mea-
sured by ﬂow cytometry on a FACSAriaII ﬂow cytometer
(Becton–Dickinson, CA, USA). The cell proliferation index (P.I.)
was analyzed using specialized software. P.I. was the sum of the
cells in all generations divided by the calculated number of original
parent cells.
2.4. Apoptosis assay
After treatment with varying concentrations of Huaier for dif-
ferent times or transfection with miRNA mimic or Huaier and
inhibitor for 48 h, A549 cells were harvested. Apoptosis was mea-
sured by propidium iodide and Annexin V-FITC double-staining
(KeyGEN BioTECH, Nanjing, China). Flow cytometry analysis was
performed as described above. Experiments were conducted three
times.
2.5. miRNA microarray
A549 cells were treated with 4 mg/mL Huaier for 48 h and the
experiments were repeated three times. Total RNA was extracted
and puriﬁed using mirVana PARIS (Ambion, TX, USA). Before miR-
NA microarray analysis, we pooled the RNA generated from three
respective times. The miRNA microarray was carried out at Shang-
hai Biotechnology Corporation (Shanghai, China). Data analysis
was performed using GeneSpringGX software 11.0 (Agilent Tech-
nologies, Santa Clara, USA).
2.6. RNA extraction and real-time PCR analysis for miRNA
Total RNA from all lung cancer cell lines was extracted using
TRIzol (Invitrogen, CA, USA). Total RNA from pulmonary alveolar
epithelial cells was purchased from PriCells (Wuhan, China). Quan-
titative real-time reverse transcription (qRT)-PCR was conducted
using TaqMan miRNA Reverse Transcription kit, TaqMan Small
RNA Assays kit, and TaqMan Universal PCR Master Mix(Applied
BioSystems, CA, USA). U6 served as an internal control. Values
are shown as 2DDCt(2(test Ct{miRNA}-test Ct{U6})-(control Ct{miRNA}-control
Ct{U6})).2.7. Transient transfection of miRNA mimic and inhibitor
miR-26b-5pmimic, inhibitor, and controls were purchased from
Ambion. The transfection was carried out with Lipofectamine
RNAiMAX Reagent (Invitrogen) according to the manufacturer’s
instructions. The miR-26b-5p mimic was used at a ﬁnal concentra-
tion of 100 nM, while the miRNA inhibitor was used at a ﬁnal con-
centration of 200 nM. Forty-eight hours after transfection,
apoptosis was analyzed, and Western blotting was performed.
2.8. miRNA target predictions
The target genes of miR-26b-5p were predicted by the miRBase
(Version 19) [12], which included MiRDB, TargetScan, PicTar, MiR-
anda, and other computational prediction methods. The predicted
targets that were related to proliferation and apoptosis were
screened ﬁrst.
2.9. Plasmid constructs and luciferase reporter assay
The full-length EZH2 30-UTR containing the putative miR-26b-
5p recognition element was ampliﬁed from the genome of human
T. Wu et al. / FEBS Letters 588 (2014) 2107–2114 2109A549 cells by PCR (sense: 50-TATCTAGACATCTGCTACCTCCTCCC-30,
antisense: 50-ATGCGGCCGCGATTCAACAAGGACAA-30). The
mutated 30-UTR of EZH2 was also ampliﬁed (sense: 50-TATCTAG
ACATCTGCTACCTCCTCCC-3). antisense: 5antisense: CTGCTACCT
CCTCCC-3). The mutated 30AT Wild-type and mutated PCR
products were cloned into the region downstream of the reporter
gene between the XbaI and NotI sites of the pRL-TK vector
(Promega, WI, USA). Two constructs were conﬁrmed by
sequencing.
Luciferase reporter assays were carried out in HEK293T cells.
HEK293T cells were seeded into 96-well plates and transfected
with either 100 ng reporter constructs or corresponding mutants
together with 10 ng of pGL3 control (Promega, WI, USA) and
10 pmol miR-26b-5p mimic or 20 pmol inhibitor using Lipofect-
amine LTX and Plus Reagent (Invitrogen). Luciferase activity wasFig. 2. miR-26b-5p was raised after Huaier treatment and was downregulated in lung
Unsupervised hierarchical clustering based on miRNA expression proﬁles in Huaier-treat
26b-5pwas conﬁrmed by qRT-PCR in A549 cells exposed to Huaier (4 mg/mL) for 48 h. Da
5p in normal pulmonary alveolar epithelial cells and six lung cancer cell lines were anal
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.measured by the Dual-Glo Luciferase Reporter Assay system (Pro-
mega). All assays were performed in triplicate.
2.10. EZH2 knockdown
Two shRNAs targeting human EZH2 and the shRNA negative
control sequence were as follows: shRNA#1, GAGGT TCAGAC
GAGCTGAT; shRNA#2, AGACTCTGAATGCAGTTGC [13]; shRNA con-
trol (OriGene, MD, USA), GGATTTCAGTCGATGTAC was a sequence
that targets ﬁreﬂy luciferase and does not match the speciﬁc
regions of human mRNA, as determined by BLAST analysis. The
shRNA constructs were separately cloned into the RNAi-ready pSI-
REN-RetroQ vector (Clontech, CA, USA) and were conﬁrmed by
sequencing. Recombinant plasmids were then transfected into
A549 cells with Lipofectamine LTX and Plus Reagent (Invitrogen).cancer cells. (A) A549 cells were treated with Huaier (4 mg/mL) or PBS for 48 h.
ed versus untreated A549 cells at fold change > 2. (B) The relative expression ofmiR-
ta are shown as relative 2DDCt values. (C) The relative expression levels ofmiR-26b-
yzed by qRT-PCR. Means from triplicate experiments in all cases, bars, SD. ⁄P < 0.05,
2110 T. Wu et al. / FEBS Letters 588 (2014) 2107–2114The primers for detection of EZH2 mRNA levels were as follows:
sense primer, 50-TTGTTGGCGGAAGCGTGTAAAATC-30; antisense
primer, 50-TTGTTGGCGGAAGCCAATGAGC-30 [14]. EZH2 mRNA
and protein levels were evaluated at 24 h and 48 h after transfec-
tion, and cell proliferation and apoptosis rates were analyzed by
ﬂow cytometry.Fig. 3. Effects ofmiR-26b-5p on cell proliferation and apoptosis in A549 cells. (A, C and E)
for 48 h. Cell proliferation was measured by CFSE assay. Cell apoptosis was assessed by ﬂ
and F) A549 cells were treated with 4 mg/mL Huaier and 200 nM miR-26b-5p inhibitor
proliferation and apoptosis assay were performed as mentioned above. Representative h2.11. Western blotting
Cells were lysed in RIPA buffer and stored at 80 C. Cell lysates
were separated by electrophoresis on 10% sodium dodecyl sulfate
(SDS)-polyacrylamide gels and then transferred onto PVDF mem-
branes. Membranes were probed with antibodies against EZH2A549 cells were transiently transfected withmiR-26b-5pmimic or control (100 nM)
ow cytometry. Results are the means ± SDs of three independent experiments. (B, D
(Huaier + inhibitor) or Huaier and inhibitor control (Huaier + control) for 48 h. Cell
istograms depicting cell proliferation and apoptosis are shown. ⁄P < 0.05, ⁄⁄P < 0.01.
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SantaCruz, CA, USA), bcl-2 (1:1000, SantaCruz), and b-actin
(1:5000, Sigma, USA) in 5% non-fat dry milk in Tris-buffered saline
with Tween-20 (TBST). A goat anti-mouse secondary antibody
(1:10,000, Sigma) was used. Labeled bands were detected using
an ECL chemiluminescent kit (Thermo, USA).
2.12. Statistical analysis
Statistical analysis was performed with Student’s t-tests. Differ-
ences with P values of less than 0.05 were considered statistically
signiﬁcant. The experiments were performed in triplicates and
repeated three times.
3. Results
3.1. Huaier suppressed proliferation and induced apoptosis of A549
cells
Huaier has been reported to exert antitumor effects in a number
of cancers [9,14–16]. Consistently, we observed that Huaier treat-
ment (2–8 mg/mL for 24–72 h) suppressed the proliferation of
A549 cells (Fig. 1A) and induced A549 cell apoptosis (Fig. 1B and
C). According to these results, we chose treatment with 4 mg/mLFig. 4. Validation of EZH2 as a target of miR-26b-5p. (A) Expression of EZH2 mRNA wa
epithelial cell line. b-actin was used as endogenous control. Each sample was analyzed in
was indicated. A mutant EZH2 30-UTR was also indicated. (C and D) HEK-293T cells were c
mimic (10 pmol) or miR-26b-5p inhibitor (20 pmol) for 48 h. Luciferase reporter assaysHuaier for 48 h as the optimal treatment time/concentration for
further experiments.
3.2. Huaier upregulated miR-26b-5p expression in A549 cells
Next, we investigated the effects of Huaier on miRNA expres-
sion proﬁles in A549 cells. Huaier treatment caused obvious
changes in miRNA expression, as shown by miRNA microarray
analysis (Fig. 2A). Of 1886 human miRNAs, 66 exhibited changes
of more than 2-fold in expression after Huaier treatment, with 33
upregulated miRNAs, including miR-150, miR-192, miR-296, miR-
26b and so on, and 33 downregulated miRNAs, including miR-
503, miR-575, miR-188, miR-494 and so on. Combining data from
microRNA chip results and literature searches, we analyzed the
functions of the differentially expressed miRNAs and identiﬁed
miR-26b as an miRNA known to be signiﬁcantly downregulated
in various cancers [17,18]and inhibits proliferation and induces
apoptosis in cancers [19,20]. Hence, we selected miR-26b-5p for
validation by the Taqman MicroRNA Assays. The upregulation in
miR-26b-5p expression level in Huaier-treated A549 cells as
revealed by real-time RT-PCR was consistent with the results from
miRNA array analysis (Fig. 2B). Importantly, we found that miR-
26b-5p expression was much lower in six NSCLC cell lines than
in normal epithelial cells (Fig. 2C). Together, these results provideds detected by qRT-PCR in six NSCLC cell lines and one normal pulmonary alveolar
triplicate. ⁄P < 0.05. (B) The predicted miR-26b-5p binding site in the 30-UTR of EZH2
otransfected with pRL-TK carrying a wt or mutant 30-UTR sequence andmiR-26b-5p
were performed three times with essentially identical results. ⁄⁄P < 0.01.
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cells was altered after Huaier treatment.
3.3. miR-26b-5p inhibited proliferation and induced apoptosis in A549
cells and inhibition of miR-26b-5p reversed the effects of Huaier
Given that miR-26b-5p was upregulated in Huaier-treated A549
cells, we transiently transfected miR-26b-5p mimic into A549 cells
or miR-26b-5p inhibitor together with 4 mg/mL Huaier toFig. 5. EZH2 knockdown in A549 cells and effects of Huaier and miR-26b-5p on the expre
PCR at 24 h post-transfection with EZH2 shRNA or the negative control. Means are from t
blotting for EZH2 protein level after induction of EZH2 shRNA expression for 48 h. (C and
shRNA-transfected A549 cells after 48 h by CFSE assay. Means ± SDs are depicted. ⁄⁄P < 0
4 mg/mL Huaier in A549 and H1299 cells. (F) Western blotting for EZH2,b-catenin and bcl
both 4 mg/mL Huaier and miR-26b-5p inhibitor (Huaier + inhibitor) or both Huaier andinvestigate the effects of miR-26b-5p. There was a signiﬁcant
reduction in the proliferation index (P.I.) following transfection
with the miR-26b-5p mimic (P.I. = 14.26 ± 0.38) compared with
the control group (P.I. = 18.54 ± 1.68; Fig. 3A and C). A549 cells
treated with 4 mg/mL Huaier and miR-26b-5p inhibitor resulted
in an increase in the P.I. (P.I. = 15.33 ± 1.63) in comparison to the
group treated with Huaier and inhibitor control (P.I. = 7.67 ± 1.53;
Fig. 3B and D). Moreover, ﬂow cytometry analysis showed that
the rate of apoptosis increased more than 2.5-fold in A549 cellsssion of EZH2, b-catenin, and bcl-2 proteins. (A) EZH2 mRNA was analyzed by qRT-
riplicate experiments in all cases, and error bars indicate SDs. ⁄⁄P < 0.01. (B) Western
D) The proliferation index and apoptosis rates were evaluated in empty vector- and
.01. (E) Western blotting for EZH2, b-catenin, and bcl-2 at 48 h post-treatment with
-2 in A549 and H1299 cells after transfection withmiR-26b-5pmimic, mimic control,
inhibitor control (Huaier + control) for 48 h. b-Actin used as an internal control.
T. Wu et al. / FEBS Letters 588 (2014) 2107–2114 2113transfected with the miR-26b-5p mimic as compared to the nega-
tive control (Fig. 3E). In addition, cells treated with 4 mg/mL Huaier
and miR-26b-5p inhibitor exhibited a 50% drop in the rate of apop-
tosis as compared with the group treated with Huaier and inhibitor
control (Fig. 3F). These results strongly suggested that miR-26b-5p
played a critical functional role in the anti-tumor effects of Huaier.
3.4. EZH2 was a direct target of miR-26b-5p
To further elucidate the mechanism through which miR-26b-5p
participated in the anti-tumor effects of Huaier, we next attempted
to identify the functional targets of miR-26b-5p. Among the target
genes predicted from miRBase, EZH2, which is upregulated in
multiple cancers [21–23] and is involved in proliferation and
apoptosis of cancer cells [24,25] became our research interest.
We ﬁrstly measured changes of EZH2 mRNA expression in
NSCLC cell lines by qRT-PCR. Interestingly, we found a negative
correlation between miR-26b-5p and EZH2; the expression of
EZH2 was upregulated in NSCLC cell lines (Fig. 4A), while miR-
26b-5p was downregulated(Fig. 2C). Additionally, luciferase repor-
ter assays demonstrated that the luciferase activity of the reporter
containing the wild-type EZH2-30-UTR, but not the seed-region
deletion mutant, was decreased after transfection with the miR-
26b-5p mimic (Fig. 4B and C). Conversely, when pRL-TK-EZH2-30-
UTR was cotransfected with miR-26b-5p inhibitor, there was an
obvious increase in luciferase activity compared with the miR-
26b-5p negative control; this effect was not observed in the mutant
group (Fig. 4D). Therefore, our data supported that the EZH2 was a
direct target of miR-26b-5p.
3.5. EZH2 knockdown in A549 cells and effects of Huaier and miR-26b-
5p on the expression of EZH2, b-catenin, and bcl-2 proteins
We next used shRNAs to knockdown EZH2 (Fig. 5A and B) in
A549 cells and investigated the effects of this intervention on
proliferation and apoptosis. Knockdown of EZH2 resulted in a
decrease in the P.I. (Fig. 5C) and an increase in apoptosis
(Fig. 5D) compared with the shRNA control. Following treatment
with 4 mg/mL Huaier or transfection with miR-26b-5p mimic for
48 h, EZH2, b-catenin, and bcl-2 protein levels were all decreased
in both A549 and H1299 cells compared with untreated cells
(Fig. 5E and F), while inhibition of miR-26b-5p attentuated the
effects of Huaier to upregulate expression of the above protein lev-
els in both A549 and H1299 cells (Fig. 5F). Taken together, Huaier
treatment and miR-26b-5p overexpression were heavily attributed
to the reduced expression of EZH2 and EZH2 related proteins.
These data further conﬁrmed that EZH2 deregulation may play
an important role in anti-tumor effects of Huaier-miR-26b-5p
pathways in lung cancer cells.
4. Discussion
The results of miRNA microarray analysis and Taqman MicroR-
NA analysis revealed that the usually low level of miR-26b-5p in
lung cancer cells was increased after Huaier treatment. Transfec-
tion of miR-26b-5p mimic into A549 cells signiﬁcantly reduced
the proliferation and increased apoptosis in A549 cells. Impor-
tantly, inhibition of miR-26b-5p reversed the anti-tumor effects of
Huaier to promote cell proliferation and suppress apoptosis. These
data demonstrated that the anti-tumor mechanisms of Huaier may
partly be mediated by the upregulation of miR-26b-5p.
EZH2 was then identiﬁed as a target ofmiR-26b-5p by luciferase
reporter assay. EZH2 is the histone H3 lysine 27 methyltransferase
of polycomb-repressive complex 2 and is overexpressed in multi-
ple cancer types [26]. Cai et al. [27] reported that Let-7a inhibitedproliferation and induced apoptosis by targeting EZH2 in nasopha-
ryngeal carcinoma cells. EZH2 was also reported to be inhibited by
miR-101 in renal cancer [28], glioblastoma [29], and prostate can-
cer [30]. Our data conﬁrmed EZH2 as a target of miR-26b-5p by
luciferase reporter assays, and shRNA-mediated EZH2 knockdown
exerted the same effects as Huaier treatment andmiR-26b-5p over-
expression. EZH2 protein levels were downregulated after Huaier
treatment and miR-26b-5p overexpression, while inhibition of
miR-26b-5p attenuated the effects of Huaier to upregulate EZH2
level. These results suggested that EZH2 may be involved in the
pathway of miR-26b-5p-medicated anti-tumor effects of Huaier.
To further investigate the mechanisms of EZH2 in Huaier-trea-
ted lung cancer cells, we detected several EZH2-related proteins.
During normal cellular functions, cytoplasmic b-catenin is main-
tained at a low level through the APC/axin/GSK-3b destruction
complex in the canonical Wnt signaling pathway [31]. However,
EZH2 can silence Wnt pathway antagonists, resulting in activa-
tion of Wnt/b-catenin signaling, and ultimately upregulating b-
catenin [32,33]. In addition, mutations in b-catenin can activate
b-catenin/Tcf signaling, increase c-Myc, elevate E2F1 expression,
and enhance Bcl-2 expression in colon tumors [34]. Thus, over-
expressed EZH2 may upregulate Bcl-2 by activation of b-catenin.
Our data demonstrated that Huaier treatment, miR-26b-5p over-
expression or inhibition affected b-catenin and Bcl-2, further link-
ing these two proteins with EZH2. Taken together, our data
suggested that EZH2, b-catenin, and Bcl-2 may contribute to sub-
sequent cell proliferation and apoptosis after Huaier treatment.
Clearly, further studies on EZH2/b-catenin/Bcl-2 pathway are
warranted.
In conclusion,miR-26b-5p-mediated repression of EZH2, b-cate-
nin, and bcl-2 may be a pivotal regulatory mechanism through
which Huaier mediates decreased cell proliferation and increased
apoptosis in lung cancer cells. Our study was the ﬁrst to uncover
the Huaier/miR-26b-5p/EZH2 pathway in lung cancer cells, provid-
ing novel mechanisms through which to understand the antitumor
effects of Huaier and further suggesting a new basis for clinical
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